{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:21:33Z","timestamp":1783570893631,"version":"3.55.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T00:00:00Z","timestamp":1647129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T00:00:00Z","timestamp":1647129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-022-02343-1","type":"journal-article","created":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T03:02:15Z","timestamp":1647140535000},"page":"215-221","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Apremilast and narrowband ultraviolet B combination therapy suppresses Th17 axis and promotes melanogenesis in vitiligo skin: a randomized, split-body, pilot study in skin types IV\u2013VI"],"prefix":"10.1007","volume":"315","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0546-6913","authenticated-orcid":false,"given":"Hee J.","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Del Duca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana B.","family":"Pavel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giselle K.","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Abittan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margot A.","family":"Chima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Kimmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Bares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Baum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Gagliotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Genece","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G.","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Guttman-Yassky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,13]]},"reference":[{"issue":"1","key":"2343_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1600-0749.2006.00355.x","volume":"20","author":"A Ta\u00efeb","year":"2007","unstructured":"Ta\u00efeb A, Picardo M (2007) The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. Pigment Cell Res 20(1):27\u201335","journal-title":"Pigment Cell Res"},{"issue":"12","key":"2343_CR2","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.1111\/jdv.16727","volume":"34","author":"RZ Conic","year":"2020","unstructured":"Conic RZ, Tamashunas NL, Damiani G, Fabbrocini G, Cantelli M, Bergfeld WF (2020) Comorbidities in pediatric alopecia areata. J Eur Acad Dermatol Venereol 34(12):2898\u20132901","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"2343_CR3","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1111\/bjd.13988","volume":"173","author":"M Malerba","year":"2015","unstructured":"Malerba M, Damiani G, Radaeli A, Ragnoli B, Olivini A, Calzavara-Pinton PG (2015) Narrowband ultraviolet B phototherapy in psoriasis reduces proinflammatory cytokine levels and improves vitiligo and neutrophilic asthma. Br J Dermatol 173(6):1544\u20131545","journal-title":"Br J Dermatol"},{"key":"2343_CR4","doi-asserted-by":"crossref","unstructured":"Mineiro Dos Santos Garrett NF, Carvalho da Costa AC, Barros Ferreira E, Damiani G, Diniz Dos Reis PE, Inoc\u00eancio Vasques C. Prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy: Systematic review and meta-analysis. PLoS One. 2021;16(8):e0255716.","DOI":"10.1371\/journal.pone.0255716"},{"issue":"1","key":"2343_CR5","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15196","volume":"35","author":"G Ciccarese","year":"2022","unstructured":"Ciccarese G, Drago F, Boldrin S, Pattaro M, Parodi A (2022) Sudden onset of vitiligo after COVID-19 vaccine. Dermatol Ther. 35(1):e15196","journal-title":"Dermatol Ther."},{"issue":"2","key":"2343_CR6","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1755-148X.2011.00945.x","volume":"25","author":"Y Kotobuki","year":"2012","unstructured":"Kotobuki Y, Tanemura A, Yang L, Itoi S, Wataya-Kaneda M, Murota H et al (2012) Dysregulation of melanocyte function by Th17-related cytokines: significance of Th17 cell infiltration in autoimmune vitiligo vulgaris. Pigment Cell Melanoma Res 25(2):219\u2013230","journal-title":"Pigment Cell Melanoma Res"},{"issue":"Suppl 1","key":"2343_CR7","first-page":"S16","volume":"3","author":"A Antonelli","year":"2015","unstructured":"Antonelli A, Ferrari SM, Fallahi P (2015) The role of the Th1 chemokine CXCL10 in vitiligo. Ann Transl Med 3(Suppl 1):S16","journal-title":"Ann Transl Med"},{"issue":"1","key":"2343_CR8","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/jocd.12517","volume":"18","author":"S Sushama","year":"2019","unstructured":"Sushama S, Dixit N, Gautam RK, Arora P, Khurana A, Anubhuti A (2019) Cytokine profile (IL-2, IL-6, IL-17, IL-22, and TNF-\u03b1) in vitiligo-New insight into pathogenesis of disease. J Cosmet Dermatol 18(1):337\u2013341","journal-title":"J Cosmet Dermatol"},{"issue":"4","key":"2343_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0018907","volume":"6","author":"CQ Wang","year":"2011","unstructured":"Wang CQ, Cruz-Inigo AE, Fuentes-Duculan J, Moussai D, Gulati N, Sullivan-Whalen M et al (2011) Th17 cells and activated dendritic cells are increased in vitiligo lesions. PLoS One. 6(4):e18907","journal-title":"PLoS One."},{"issue":"3","key":"2343_CR10","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1111\/pcmr.12355","volume":"28","author":"L Zhou","year":"2015","unstructured":"Zhou L, Shi YL, Li K, Hamzavi I, Gao TW, Huggins RH et al (2015) Increased circulating Th17 cells and elevated serum levels of TGF-beta and IL-21 are correlated with human non-segmental vitiligo development. Pigment Cell Melanoma Res 28(3):324\u2013329","journal-title":"Pigment Cell Melanoma Res"},{"issue":"2","key":"2343_CR11","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.jid.2016.09.016","volume":"137","author":"JM Richmond","year":"2017","unstructured":"Richmond JM, Bangari DS, Essien KI, Currimbhoy SD, Groom JR, Pandya AG et al (2017) Keratinocyte-derived chemokines orchestrate T-Cell positioning in the epidermis during vitiligo and may serve as biomarkers of disease. J Invest Dermatol 137(2):350\u2013358","journal-title":"J Invest Dermatol"},{"issue":"7","key":"2343_CR12","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/jid.2011.463","volume":"132","author":"JE Harris","year":"2012","unstructured":"Harris JE, Harris TH, Weninger W, Wherry EJ, Hunter CA, Turka LA (2012) A mouse model of vitiligo with focused epidermal depigmentation requires IFN-\u03b3 for autoreactive CD8+ T-cell accumulation in the skin. J Invest Dermatol. 132(7):1869\u201376","journal-title":"J Invest Dermatol."},{"issue":"8","key":"2343_CR13","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/j.jid.2019.11.031","volume":"140","author":"A Khemis","year":"2020","unstructured":"Khemis A, Fontas E, Moulin S, Montaudi\u00e9 H, Lacour JP, Passeron T (2020) Apremilast in combination with narrowband UVB in the treatment of vitiligo: a 52-week monocentric prospective randomized placebo-controlled study. J Invest Dermatol 140(8):1533\u20137.e2","journal-title":"J Invest Dermatol"},{"issue":"6","key":"2343_CR14","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1111\/bjd.14416","volume":"174","author":"XX Wang","year":"2016","unstructured":"Wang XX, Wang QQ, Wu JQ, Jiang M, Chen L, Zhang CF et al (2016) Increased expression of CXCR3 and its ligands in patients with vitiligo and CXCL10 as a potential clinical marker for vitiligo. Br J Dermatol 174(6):1318\u20131326","journal-title":"Br J Dermatol"},{"issue":"1","key":"2343_CR15","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1038\/s41467-019-09963-8","volume":"10","author":"MK Tulic","year":"2019","unstructured":"Tulic MK, Cavazza E, Cheli Y, Jacquel A, Luci C, Cardot-Leccia N et al (2019) Innate lymphocyte-induced CXCR3B-mediated melanocyte apoptosis is a potential initiator of T-cell autoreactivity in vitiligo. Nat Commun 10(1):2178","journal-title":"Nat Commun"},{"issue":"4","key":"2343_CR16","doi-asserted-by":"publisher","first-page":"285","DOI":"10.37349\/ei.2021.00019","volume":"1","author":"K Orihara","year":"2021","unstructured":"Orihara K (2021) Skin and immune cells crosstalk via circadian regulations. Explor Immunol 1(4):285\u2013294","journal-title":"Explor Immunol"},{"issue":"6159","key":"2343_CR17","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1126\/science.1243884","volume":"342","author":"X Yu","year":"2013","unstructured":"Yu X, Rollins D, Ruhn KA, Stubblefield JJ, Green CB, Kashiwada M et al (2013) TH17 cell differentiation is regulated by the circadian clock. Science 342(6159):727\u2013730","journal-title":"Science"},{"issue":"5","key":"2343_CR18","doi-asserted-by":"publisher","first-page":"451","DOI":"10.2174\/138920010791526105","volume":"11","author":"L Guerra","year":"2010","unstructured":"Guerra L, Dellambra E, Brescia S, Raskovic D (2010) Vitiligo: pathogenetic hypotheses and targets for current therapies. Curr Drug Metab 11(5):451\u2013467","journal-title":"Curr Drug Metab"},{"issue":"12","key":"2343_CR19","first-page":"1514","volume":"135","author":"MD Njoo","year":"1999","unstructured":"Njoo MD, Westerhof W, Bos JD, Bossuyt PM (1999) The development of guidelines for the treatment of vitiligo. Clinical epidemiology unit of the Istituto Dermopatico dell\u2019Immacolata-Istituto di Recovero e Cura a Carattere Scientifico (IDI-IRCCS) and the archives of dermatology. Arch Dermatol. 135(12):1514\u201321","journal-title":"Arch Dermatol."},{"issue":"1","key":"2343_CR20","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/j.1365-4632.2004.02329.x","volume":"44","author":"AJ Kanwar","year":"2005","unstructured":"Kanwar AJ, Dogra S, Parsad D, Kumar B (2005) Narrow-band UVB for the treatment of vitiligo: an emerging effective and well-tolerated therapy. Int J Dermatol 44(1):57\u201360","journal-title":"Int J Dermatol"},{"issue":"2","key":"2343_CR21","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/j.1468-3083.2006.01413.x","volume":"20","author":"D Parsad","year":"2006","unstructured":"Parsad D, Kanwar AJ, Kumar B (2006) Psoralen-ultraviolet A vs. narrow-band ultraviolet B phototherapy for the treatment of vitiligo. J Eur Acad Dermatol Venereol. 20(2):175\u20137","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"1","key":"2343_CR22","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/phpp.12277","volume":"33","author":"R Li","year":"2017","unstructured":"Li R, Qiao M, Wang X, Zhao X, Sun Q (2017) Effect of narrow band ultraviolet B phototherapy as monotherapy or combination therapy for vitiligo: a meta-analysis. Photodermatol Photoimmunol Photomed 33(1):22\u201331","journal-title":"Photodermatol Photoimmunol Photomed"},{"issue":"3","key":"2343_CR23","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1177\/1203475419833609","volume":"23","author":"N Relke","year":"2019","unstructured":"Relke N, Gooderham M (2019) The use of janus kinase inhibitors in vitiligo: a review of the literature. J Cutan Med Surg 23(3):298\u2013306","journal-title":"J Cutan Med Surg"},{"issue":"4","key":"2343_CR24","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.jaad.2017.05.043","volume":"77","author":"LY Liu","year":"2017","unstructured":"Liu LY, Strassner JP, Refat MA, Harris JE, King BA (2017) Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. J Am Acad Dermatol 77(4):675\u201382.e1","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"2343_CR25","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1001\/jamadermatol.2015.1520","volume":"151","author":"BG Craiglow","year":"2015","unstructured":"Craiglow BG, King BA (2015) Tofacitinib citrate for the treatment of vitiligo: a pathogenesis-directed therapy. JAMA Dermatol 151(10):1110\u20131112","journal-title":"JAMA Dermatol"},{"issue":"4","key":"2343_CR26","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1111\/j.1476-5381.2009.00559.x","volume":"159","author":"PH Schafer","year":"2010","unstructured":"Schafer PH, Parton A, Gandhi AK, Capone L, Adams M, Wu L et al (2010) Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol 159(4):842\u2013855","journal-title":"Br J Pharmacol"},{"issue":"5","key":"2343_CR27","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1185\/030079908X301866","volume":"24","author":"AB Gottlieb","year":"2008","unstructured":"Gottlieb AB, Strober B, Krueger JG, Rohane P, Zeldis JB, Hu CC et al (2008) An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. Curr Med Res Opin 24(5):1529\u20131538","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"2343_CR28","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13075-019-1901-3","volume":"21","author":"A Kavanaugh","year":"2019","unstructured":"Kavanaugh A, Gladman DD, Edwards CJ, Schett G, Guerette B, Delev N et al (2019) Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1\u20133 pooled analysis. Arthritis Res Ther 21(1):118","journal-title":"Arthritis Res Ther"},{"issue":"16","key":"2343_CR29","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1056\/NEJMoa1408684","volume":"372","author":"G Hatemi","year":"2015","unstructured":"Hatemi G, Melikoglu M, Tunc R, Korkmaz C, Turgut Ozturk B, Mat C et al (2015) Apremilast for Beh\u00e7et\u2019s syndrome\u2013a phase 2, placebo-controlled study. N Engl J Med 372(16):1510\u20131518","journal-title":"N Engl J Med"},{"issue":"1","key":"2343_CR30","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1186\/s13075-015-0771-6","volume":"17","author":"M Perez-Aso","year":"2015","unstructured":"Perez-Aso M, Montesinos MC, Mediero A, Wilder T, Schafer PH, Cronstein B (2015) Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors. Arthritis Res Ther 17(1):249","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"2343_CR31","first-page":"888","volume":"12","author":"AB Gottlieb","year":"2013","unstructured":"Gottlieb AB, Matheson RT, Menter A, Leonardi CL, Day RM, Hu C et al (2013) Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study. J Drugs Dermatol 12(8):888\u2013897","journal-title":"J Drugs Dermatol"},{"issue":"9","key":"2343_CR32","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1016\/j.cellsig.2014.05.014","volume":"26","author":"PH Schafer","year":"2014","unstructured":"Schafer PH, Parton A, Capone L, Cedzik D, Brady H, Evans JF et al (2014) Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cell Signal 26(9):2016\u20132029","journal-title":"Cell Signal"},{"issue":"20","key":"2343_CR33","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1101\/gad.1937710","volume":"24","author":"M Khaled","year":"2010","unstructured":"Khaled M, Levy C, Fisher DE (2010) Control of melanocyte differentiation by a MITF-PDE4D3 homeostatic circuit. Genes Dev 24(20):2276\u20132281","journal-title":"Genes Dev"},{"issue":"7109","key":"2343_CR34","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/nature05098","volume":"443","author":"JA D'Orazio","year":"2006","unstructured":"D\u2019Orazio JA, Nobuhisa T, Cui R, Arya M, Spry M, Wakamatsu K et al (2006) Topical drug rescue strategy and skin protection based on the role of Mc1r in UV-induced tanning. Nature 443(7109):340\u2013344","journal-title":"Nature"},{"issue":"4","key":"2343_CR35","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12923","volume":"32","author":"I Majid","year":"2019","unstructured":"Majid I, Imran S, Batool S (2019) Apremilast is effective in controlling the progression of adult vitiligo: A case series. Dermatol Ther. 32(4):e12923","journal-title":"Dermatol Ther."},{"key":"2343_CR36","first-page":"2386234","volume":"2017","author":"SB Huff","year":"2017","unstructured":"Huff SB, Gottwald LD (2017) Repigmentation of Tenacious Vitiligo on Apremilast. Case Rep Dermatol Med 2017:2386234","journal-title":"Case Rep Dermatol Med"},{"issue":"6","key":"2343_CR37","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/j.jaad.2020.12.073","volume":"85","author":"HJ Kim","year":"2021","unstructured":"Kim HJ, Singer G, Abittan BJ, Chima MA, Kimmel G, Bares J et al (2021) Combination of apremilast and narrowband ultraviolet B light in the treatment of generalized vitiligo in skin phototypes IV to VI: A randomized split-body pilot study. J Am Acad Dermatol. 85(6):1657\u20131660","journal-title":"J Am Acad Dermatol."},{"issue":"1","key":"2343_CR38","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1210\/en.2014-1238","volume":"156","author":"R Saternus","year":"2015","unstructured":"Saternus R, Pilz S, Gr\u00e4ber S, Kleber M, M\u00e4rz W, Vogt T et al (2015) A closer look at evolution: Variants (SNPs) of genes involved in skin pigmentation, including EXOC2, TYR, TYRP1, and DCT, are associated with 25(OH)D serum concentration. Endocrinology 156(1):39\u201347","journal-title":"Endocrinology"},{"issue":"5","key":"2343_CR39","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/pcmr.12611","volume":"30","author":"HE Seberg","year":"2017","unstructured":"Seberg HE, Van Otterloo E, Cornell RA (2017) Beyond MITF: Multiple transcription factors directly regulate the cellular phenotype in melanocytes and melanoma. Pigment Cell Melanoma Res 30(5):454\u2013466","journal-title":"Pigment Cell Melanoma Res"},{"issue":"9","key":"2343_CR40","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1080\/17425255.2016.1206886","volume":"12","author":"L Bianchi","year":"2016","unstructured":"Bianchi L, Del Duca E, Romanelli M, Saraceno R, Chimenti S, Chiricozzi A (2016) Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis. Expert Opin Drug Metab Toxicol 12(9):1121\u20131128","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2343_CR41","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/1471-2148-8-74","volume":"8","author":"S Alonso","year":"2008","unstructured":"Alonso S, Izagirre N, Smith-Zubiaga I, Gardeazabal J, D\u00edaz-Ram\u00f3n JL, D\u00edaz-P\u00e9rez JL et al (2008) Complex signatures of selection for the melanogenic loci TYR, TYRP1 and DCT in humans. BMC Evol Biol 8:74","journal-title":"BMC Evol Biol"},{"issue":"3","key":"2343_CR42","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1034\/j.1600-0749.2003.00055.x","volume":"16","author":"B Wehrle-Haller","year":"2003","unstructured":"Wehrle-Haller B (2003) The role of Kit-ligand in melanocyte development and epidermal homeostasis. Pigment Cell Res 16(3):287\u2013296","journal-title":"Pigment Cell Res"},{"issue":"1","key":"2343_CR43","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1001\/jamadermatol.2014.1875","volume":"151","author":"HW Lim","year":"2015","unstructured":"Lim HW, Grimes PE, Agbai O, Hamzavi I, Henderson M, Haddican M et al (2015) Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. JAMA Dermatol 151(1):42\u201350","journal-title":"JAMA Dermatol"},{"issue":"1","key":"2343_CR44","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","volume":"73","author":"K Papp","year":"2015","unstructured":"Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RG et al (2015) Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol 73(1):37\u201349","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"2343_CR45","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1111\/bjd.14164","volume":"173","author":"C Paul","year":"2015","unstructured":"Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferrandiz C et al (2015) Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol 173(6):1387\u20131399","journal-title":"Br J Dermatol"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-022-02343-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-022-02343-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-022-02343-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T02:27:23Z","timestamp":1676860043000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-022-02343-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,13]]},"references-count":45,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["2343"],"URL":"https:\/\/doi.org\/10.1007\/s00403-022-02343-1","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,13]]},"assertion":[{"value":"6 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Lebwohl has received research funds from Abbvie, Amgen, Arcutis, AstraZeneca, Boehringer Ingelheim, Celgene, Clinuvel, Corrona.Inc, Eli Lilly, Foundation for Research & Education in Dermatology, Incyte, Janssen Research & Development, Kadmon Corp, Leo Pharmaceuticals, MedImmune, Novartis, Ortho Dermatologics, Pfizer, Sciderm, UCB.Inc, and ViDac, and is a consultant for Allergan, Almirall, Arcutis, Boehringer Ingelheim, Bristol-Myers Squibb, Castle Biosciences, Leo Pharma, Menlo, Mitsubishi, Neuroderm, Pfizer, Promius\/Dr. Reddy's Laboratories, Theravance, and Verrica. Dr. Guttman has received research funds from Abbvie, Celgene, Eli Lilly, Janssen, MedImmune\/AstraZeneca, Novartis, Pfizer, Regeneron, Vitae, Glenmark, Galderma, Asana, Innovaderm, Dermira and UCB, and is also a consultant for Sanofi Aventis, Regeneron, Stiefel\/GlaxoSmithKline, MedImmune, Celgene, Anacor, AnaptysBio, Dermira, Galderma, Glenmark, Novartis, Pfizer, Vitae, Leo Pharma, Abbvie, Eli Lilly, Kyowa, Mitsubishi Tanabe, Asana Biosciences, and Promius. Other authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}